

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Facchinetti 1



| Section 1. | Identifying Inform | ation | | | | | | |
|---|----------------------------|-----------------------------------|------------------------|--------------------------|-------------------|--|--|--|
| Given Name (File Francesco | | 2. Surname (Last N Facchinetti | ame) | 3. Date 16-March-2021 | | | | |
| | responding author? | ✓ Yes No | | | <u> </u> | | | |
| 5. Manuscript Title First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis. | | | | | | | | |
| 6. Manuscript Ider TLCR-21-15 | ntifying Number (if you kn | ow it) | | | | | | |
| | l | | | | | | | |
| Section 2. | The Work Under Co | onsideration for | Publication | | | | | |
| Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes Vo | | | | | | | | |
| Section 3. | Relevant financial | activities outsid | e the submitted | work. | | | | |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes No | | | | | | | | |
| If yes, please fill o | out the appropriate info | ormation below. | | | | | | |
| Name of Entity | | Grant? Persona | Non-Financial Support? | Other? Co | omments | | | |
| BMS | | | | Edit | torial activities | | | |
| Roche | | | | Edit | torial activities | | | |
| | | | | | | | | |
| Section 4. Intellectual Property Patents & Copyrights | | | | | | | | |
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo | | | | | | | | |

Facchinetti 2



| Section 5. Polationships not sovered above |
|--|
| Relationships not covered above |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? |
| Yes, the following relationships/conditions/circumstances are present (explain below): |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below. |
| Dr. Facchinetti reports personal fees from BMS, personal fees from Roche, outside the submitted work; . |

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Facchinetti 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Di Maio 1



| Section 1. | Identifying Inform | ation | | | | | |
|--|----------------------------|----------------------------|-----------------------------------|------------------------|---|---|-------|
| 1. Given Name (Fir Massimo | rst Name) | 2. Surnan Di Maio | ne (Last Nar | ne) | | 3. Date 16-March-2021 | |
| 4. Are you the cor | responding author? | Yes | ✓ No | - | Corresponding Author's Name Francesco Facchinetti | | |
| 5. Manuscript Title First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis. | | | | | | | |
| 6. Manuscript Ider TLCR-21-15 | ntifying Number (if you kn | ow it) | | | | | |
| Section 2. | The Work Under Co | onsiderat | tion for P | ublication | | | |
| any aspect of the s statistical analysis, | ubmitted work (including | but not lim | ited to grar | | | nt, commercial, private foundation, ıdy design, manuscript preparation, | |
| Section 3. | Relevant financial a | activities | outside ' | the submitted | work. | | |
| of compensation clicking the "Add Are there any rele |) with entities as descri | oed in the ort relationst? | instruction inships that es | ns. Use one line fo | or each en | ial relationships (regardless of ar tity; add as many lines as you ne 36 months prior to publicatio | ed by |
| Name of Entity | | Grant? | Personal Fees? | Non-Financial Support? | Other? | Comments | |
| Astra-Zeneca | | | √ | | | | |
| Pfizer | | | ✓ | | | | |
| BMS | | | √ | | | | |
| MSD | | | ✓ | | | | |
| Eisai | | | √ | | | | |
| Janssen | | | ✓ | | | | |
| Astellas | | | ✓ | | | | |
| Takeda | | | √ | | | | |

Di Maio 2



| Name of Entity | Grant? Personal Fees? | Non-Financial Support? | Other? Comments | | | | | | |
|---|---|------------------------|---------------------------|------------------|--|--|--|--|--|
| Fesaro - GSK | ✓ | | | | | | | | |
| | | | | | | | | | |
| Section 4. Intellectual Propert | y Patents & Cop | yrights | | | | | | | |
| | Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo | | | | | | | | |
| Section 5. Relationships not c | overed above | | | | | | | | |
| Are there other relationships or activities potentially influencing, what you wrote i | | | nfluenced, or that give t | he appearance of | | | | | |
| Yes, the following relationships/cond | itions/circumstances | are present (exp | lain below): | | | | | | |
| No other relationships/conditions/cir | cumstances that pre | sent a potential c | onflict of interest | | | | | | |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. | | | | | | | | | |
| Section 6. Disclosure Stateme | nt | | | | | | | | |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below. | | | | | | | | | |
| Dr. Di Maio reports personal fees from Astra-Zeneca, personal fees from Pfizer, personal fees from BMS, personal fees from MSD, personal fees from Eisai, personal fees from Janssen, personal fees from Astellas, personal fees from Takeda, grants from Tesaro - GSK, outside the submitted work; . | | | | | | | | | |
| | | | | | | | | | |

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Di Maio 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Perrone 1



| Section 1. Identifying Inform | nation | | | | | | | |
|---|-----------------------------------|---|--|--|--|--|--|--|
| 1. Given Name (First Name) Fabiana | 2. Surname (Last Name) Perrone | 3. Date 16-March-2021 | | | | | | |
| 4. Are you the corresponding author? | Yes 🗸 No | Corresponding Author's Name Francesco Facchinetti | | | | | | |
| meta-analysis. | | vith poor performance status: A systematic review and | | | | | | |
| 6. Manuscript Identifying Number (if you kr TLCR-21-15 | now it) | _ | | | | | | |
| Section 2. The Work Under C | | | | | | | | |
| Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No | | | | | | | | |
| Section 3. Relevant financial | activities outside the s | submitted work. | | | | | | |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes Vo | | | | | | | | |
| Section 4. Intellectual Proper | rty Patents & Copyri | ghts | | | | | | |
| Do you have any patents, whether plan | ned, pending or issued, br | roadly relevant to the work? Yes Vo | | | | | | |

Perrone 2



| Section 5. Polotionships not severed above |
|---|
| Relationships not covered above |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? |
| Yes, the following relationships/conditions/circumstances are present (explain below): |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below. |
| Dr. Perrone has nothing to disclose. |

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Perrone 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



| | Section 1. | Identifying Inform | ation | | | | | |
|--|--|----------------------------|------------------------------------|--------------------------|------------------------|---|--|----------|
| | 1. Given Name (Fir Marcello | rst Name) | 2. Surnar Tiseo | ne (Last Nar | me) | | 3. Date 16-March-2021 | |
| | 4. Are you the corr | responding author? | Yes | √ No | - | Corresponding Author's Name Francesco Facchinetti | | |
| 5. Manuscript Title First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis. | | | | | | | | <u> </u> |
| | 6. Manuscript Iden TLCR-21-15 | ntifying Number (if you kn | ow it) | | | | | |
| | Section 2. | The Work Under Co | onsiderat | tion for P | ublication | | | |
| | any aspect of the su statistical analysis, | ubmitted work (including | but not lim | nited to grar | | | nt, commercial, private foundation, Idy design, manuscript preparation, | |
| | Section 3. | Relevant financial a | activities | outside | the submitted | work. | | |
| | of compensation clicking the "Add Are there any rele |) with entities as descri | bed in the port relation st? | instruction inships that | ns. Use one line fo | or each en | ial relationships (regardless of ar tity; add as many lines as you ne 36 months prior to publicatio | eed by |
| | Name of Entity | | Grant? | Personal Fees? | Non-Financial Support? | Other? | Comments | |
| Α | stra-Zeneca | | ✓ | √ | | | | |
| В | oehringer Ingelheim | 1 | ✓ | ✓ | | | | |
| P | fizer | | ✓ | | | | | |
| Eli-Lilly | | | ✓ | | | | | |
| В | MS | | | ✓ | | | | |
| | lovartis | | | ✓ | | | | |
| | oche ISD | | ✓ | ✓ | | | | |
| ٧ | 130 | | V | V | | | | |



| Name of Entity | Grant? Personal Fees? | Non-Financial Support? | ther? Comments | | | | |
|---|-----------------------|------------------------|----------------------------|---------------------|--|--|--|
| Otsuka | ✓ | | | | | | |
| Pierre Fabre | ✓ | | | | | | |
| Section 4. Intellectual Braneut | | | | | | | |
| Intellectual Propert | y Patents & Co | pyrights | | | | | |
| Do you have any patents, whether planne | ed, pending or issue | ed, broadly relevant | to the work? Yes | ✓ No | | | |
| Section 5. Relationships not co | overed above | | | | | | |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. | | | | | | | |
| Section 6. Disclosure Statemen | nt | | | | | | |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below. | | | | | | | |
| Dr. Tiseo reports grants and personal fee from Pfizer, personal fees from Eli-Lilly, p fees from Roche, grants and personal fee work; . | ersonal fees from B | MS, grants and perso | onal fees from Novartis, g | grants and personal | | | |



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.